Jonathan Schramm

3 days ago | securities.io | Jonathan Schramm

Why Cybersecurity Stocks Are BoomingWhile our economy has been computerized for a while, it is still getting increasingly connected. Data that used to be stored locally is now in the cloud. Work is not done in one office but remotely by delocalized teams, often in multiple countries. Most of the software we use is in the cloud. This means that vital or confidential business data is constantly circulated back and forth through the Internet, and virtually all devices are connected at all times.

4 days ago | securities.io | Jonathan Schramm

Better Agriculture NeededAs our civilization faces the conjunction of rising population and climate instability, the question of food security is rising back to the forefront of the important issues to tackle. Adding to this risk, many others are adding to the list, making the issue even more sensitive, like the ongoing damage to biodiversity and species extinctions, pollution, erosion of fertile soil, urbanization of arable lands, etc.

5 days ago | securities.io | Jonathan Schramm

Vertex’s Journey: From Cystic Fibrosis to Biotech LeaderMost biotech companies fail, and the ones that succeed usually do so by focusing on a specific disease that was previously incurable, or poorly treated. This is exactly what Vertex Pharmaceuticals did with cystic fibrosis, a rare genetic disease causing damage to the lungs, affecting 109,000 people around the world, most of them in the USA, Europe, Australia, and Canada.

1 week ago | securities.io | Jonathan Schramm

Why LNG Is Crucial for the Energy TransitionAs the world moves away from fossil fuels, the dream of a fully renewable-powered economy might seem within reach. It is however not so simple. One reason is that building up renewable power capacity takes time, and even with trillions put into wind farms and solar parks, most of the world's energy still comes from fossil fuels.

1 week ago | securities.io | Jonathan Schramm

The New Drug BlockbustersSince its effects on weight loss became well known, the diabetes drug semaglutide, commercialized by Novo Nordisk (NVO -0.44%) under the brand name Wegovy, has taken the pharmaceutical industry by storm. Since semaglutide was found to help with heart diseases and cardiovascular risks, irrespective of whether the patient is already suffering from it or not, and whether the patient is diabetic or not.